Search Result

Results for "

P. berghei

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Bacterial (1) Dihydroorotate Dehydrogenase (3) DNA/RNA Synthesis (1) Endogenous Metabolite (2) HDAC (1) HSP (1) Parasite (23) PI4K (1) Reference Standards (1)
By Research Areas:	Infection (23) Inflammation/Immunology (2)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W071746

Linolelaidic acid 1 Publications Verification Linoelaidic acid	Endogenous Metabolite Parasite Apoptosis	Infection Inflammation/Immunology
Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections .

HY-15975

GNF179	Parasite	Infection
GNF179 is an optimized 8,8-dimethyl imidazolopiperazine analog that exhibits antimalarial potency (IC₅₀ of 4.8 nM against the multidrug resistant strain W2). GNF179 is orally active .

HY-128204

AN3661 2 Publications Verification	Parasite	Infection
AN3661, a potent antimalarial lead compound, targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue subunit 3 (PfCPSF3). AN3661 inhibits Plasmodium falciparum laboratory-adapted strains (mean IC₅₀=32 nM), Ugandan field isolates (mean ex vivo IC₅₀=64 nM), and murine P. berghei and P. falciparum infections .

HY-119046

SNX-0723 2 Publications Verification	HSP Parasite	Infection
SNX-0723 is a potent Hsp90 Inhibitor with anti-Plasmodium activity. SNX-0723 shows high binding affinity for HsHsp90 and PfHsp90 with K_is of 4.4 and 47 nM, respectively. SNX-0723 inhibits liver-stage P. berghei ANKA parasites with the EC₅₀ of 3.3 μM .

HY-17656

C3361	Parasite	Infection
C3361 is a moderate specific Plasmodium falciparum hexose transporter 1 (PfHT1) and Plasmodium berghei hexose transporter 1 (PbHT1) inhibitor with K_i values of 8.6 and 9.4 μM. C3361 inhibits TgGT1 with a K_i of 82 μM. C3361 attenuates hepatic (IC₅₀ = 15 μM) and ookinete development of P. berghei. C3361 can suppress the growth of blood-stage parasites. C3361 can be used for the research of infection, such as malaria .

HY-W071746R

Linolelaidic acid (Standard) Linoelaidic acid (Standard)	Reference Standards Endogenous Metabolite Parasite Apoptosis	Infection Inflammation/Immunology
Linolelaidic acid (Standard) is the analytical standard of Linolelaidic acid. This product is intended for research and analytical applications. Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections[1][2][3].

HY-120924

BRD9185	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite	Infection
BRD9185 is a Dihydroorotate dehydrogenase (DHODH) inhibitor, with an EC₅₀ of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model .

HY-155688

Antimalarial agent 29	Parasite	Infection
Antimalarial agent 29 (compound 16) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC₅₀ of 5.2 μM .

HY-155689

Antimalarial agent 30	Parasite	Infection
Antimalarial agent 30 (compound 11) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC₅₀ of 5.2 μM .

HY-118537

ICI 56780	Parasite	Infection
ICI 56780 is an antimalarial agent, that exhibits etiological prevention and blood schizonticidal activity in rodent malaria models. ICI 56780 develops parasite resistance in P. berghei infected mice .

HY-152614

Antimalarial agent 19	Parasite	Infection
Antimalarial agent 19 (compound 6e) is an antimalarial active agent. Antimalarial agent 19 has antimalarial activity for the blood stage of P. falciparum K1 and P. berghei with EC₅₀ values of 0.3 µM, 15.3 µM, respectively. Antimalarial agent 19 has good aqueous solubility, intestinal permeability and microsomal stability compared to gamhepathiopine .

HY-116736

BRD7539	Dihydroorotate Dehydrogenase Parasite	Infection
BRD7539 is a PfDHODH inhibitor (IC₅₀ = 0.033 μM). BRD7539 has potent activity against both multidrug-resistant asexual blood-stage (P. falciparum, Dd2 strain, EC₅₀ = 0.010 μM) and liver-stage (P. berghei, EC₅₀ = 0.015 μM) parasites .

HY-124112

PAM 1392	Parasite	Infection
PAM 1392 is active orally against Plasmodium berghei in mice, *P. cynofologi* and *P. knowlesi* in monkeys and *Trypanosoma cruzi* in tissue cultures of mice, and *hemolytic streptococci* in vitro. PAM 1392 has antimalarial and antitrypanosomal activities, which is proming for rasearch of drug-resistant malaria .

HY-120462

Genz-669178	Dihydroorotate Dehydrogenase Parasite	Infection
Genz-669178 is an inhibitor for dihydroorotate dehydrogenase (DHODH) with IC₅₀ of 0.015-0.05 μM in Plasmodium spp.. Genz-669178 inhibits P. berghei, P. falciparum strains 3D7 and Dd2 with IC₅₀ of 0.068, 0.008 and 0.01 μM, respectively. Genz-669178 exhibits anti-malarial efficacy in P. berghei-infected mice with ED₅₀ of 13-21 mg/kg/day. Genz-669178 exhibits good pharmacokinetic characteristics in mice .

HY-155536

Antimalarial agent 28	Parasite	Infection
Antimalarial agent 28 (Compound 2i) is an antiplasmodial agent. Antimalarial agent 28 inhibits P. berghei, with IC₅₀s of 0.561 μM, 0.14 μM, 4.34 μM for Liver stage, early gametocytes and ring stages of P. falciparum .

HY-178147

Antimalarial agent 52	Parasite	Infection
Antimalarial agent 52 is an orally active formation of synthetic hemozoin (β-hematin) inhibitor with an IC₅₀ of 6.6 μM. Antimalarial agent 52 exhibits in vitro antiplasmodial activity against P. falciparum Pf3D7, PfDd2 strains and P. knowlesi with IC₅₀s of 6.1, 6.4 and 3.3 nM. Antimalarial agent 52 remain highly effective against multidrug-resistant strains and demonstrates curative activity in the P. berghei mouse model .

HY-173312

Antimalarial agent 49	Parasite	Infection
Antimalarial agent 49 is an orally active antimalarial compound. Antimalarial agent 49 inhibits growth of Pf3D7 and PfK1 strains (IC₅₀: 0.84 μM and 0.4 μM respectively). Antimalarial agent 49 has antimalarial activity and inhibits the development of P. berghei liver stages. Antimalarial agent 49 can be used in the study of Plasmodium infection .

HY-111817A

(Rac)-ACT-451840	Parasite	Infection
(Rac)-ACT-451840 is an isomer of ACT-451840 that exhibits significant antimalarial effects. (Rac)-ACT-451840 exhibits significant antimalarial activity against P. berghei-infected mice at a dose of 20 mg/kg (ED90=13 mg/kg), and has an inhibitory effect at a dose of 300 mg/kg. The ED90 of (Rac)-ACT-451840 in the P. falciparum humanized immunodeficient mouse model is 3.7 mg/kg. (Rac)-ACT-451840 is similar to artemisinin, with a rapid onset of action but requires repeated high doses.

HY-147849

JMI-105	Parasite	Infection
JMI-105 is a potent PfFP-2 (Plasmodium falciparum falcipain-2 protease) inhibitor. JMI-105 inhibits the growth of CQ ^S (3D7; IC₅₀=8.8 µM) and CQ ^R (RKL-9; IC₅₀=14.3 µM) strains of P. falciparum. JMI-105 significantly decreases parasitemia and prolonged host survival in a murine model with P. berghei ANKA infection. JMI-105 has the potential to be used as an anti-malarial agent .

HY-117599

JPC-3210	Parasite	Infection
JPC-3210 is an orally active aminomethylphenol. JPC-3210 exhibits anti-malarial activity with a mean IC₅₀ ranging from 2.5 to 19 nM. JPC-3210 works by inhibiting the hemoglobin digestion pathway and promoting regulators of protein translation. JPC-3210 can inhibit CYP2D6 and CYP3A4 isozymes. JPC-3210 suppresses P. berghei* infection in mice model. JPC-3210 possesses prophylactic protection in vivo. JPC-3210 can be studied in research on malaria prevention .*

HY-155846

Antileishmanial agent-22	Parasite Bacterial	Infection
Antileishmanial agent-22 (compound 15b) is a parasite inhibitor and an antibacterial agent, with antileishmanial, antimalarial, and anti-tubercular activities. Antileishmanial agent-22 inhibits leishmanial (IC₅₀=0.408 μM) based on antifolate mechanism. And, Antileishmanial agent-22 inhibits Folic acid and Folinic acid at 100 μM with inhibitory rates of 88% and 94%, respectively. Antileishmanial agent-22 inhibits P. berghei in vivo and in vitro, with 96.67% suppression under 48.4 μM/kg/day and 0.038 μM (IC₅₀), respectively. Moreover, Antileishmanial agent-22 inhibits M. tuberculosis with MIC of 28.44 μM .

HY-18746

KAI-407	Parasite PI4K	Infection
KAI-407 is an orally active inhibitor of Plasmodium PI4K kinase, which can broadly inhibit multiple stages of the parasite lifecycle. KAI-407 exhibits EC₅₀s of for the blood stage of malignant Plasmodium of 81 nM; for the liver schizonts of P. yoelii of 88 nM; and IC₅₀s for the liver schizonts and dormant bodies of P. cynomolgi of 0.64 μM and 0.69 μM respectively. KAI-407 can prevent Plasmodium berghei infection 100%. KAI-407 can be used for the study of vivax malaria .

HY-181010

HDAC1-IN-12	HDAC Parasite	Infection
HDAC1-IN-12 is a Plasmodium falciparum HDAC1 (PfHDAC1) inhibitor with an IC₅₀ of 4.1 nM against Pf3D7. HDAC1-IN-12 inhibits PfHDAC1, upregulates histone H₃ acetylation in P. falciparum parasites, downregulates malaria invasion-related gene expression, and exhibits favorable safety profiles, improved physicochemical properties, and potent in vivo antimalarial activity. HDAC1-IN-12 can be used for the research of malaria .

Linolelaidic acid 1 Publications Verification Linoelaidic acid	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Parasite Apoptosis
Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections .

Linolelaidic acid (Standard) Linoelaidic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Parasite Apoptosis
Linolelaidic acid (Standard) is the analytical standard of Linolelaidic acid. This product is intended for research and analytical applications. Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

P. berghei

Inhibitors & Agonists

NaturalProducts

Natural
Products